Member Info for BertieBassett

Merger and acquisition (M&A) activity has surfaced exciting opportunities for growth and outreach. The Company intends to continue with these discussions in 2021.

thank you!!!

Will check, thanks

whenever we move forward two steps, we move back one! Grrrrrrrrrrr
-- BB --

Getting no cogent advice from Lloyds. Can anyone advise if Lloyds can deal with Accustem when it lists on NASDAQ or will we need to move the shares to another broker? thank you
-- BB --

well, RENX has a NASDAQ listing - renalytixai - TB has said he does not want to go down this route ... but maybe one day ...
-- BB --

Does anyone have any AI comparable companies? I do like Renx (mcap: 670m, 72 m shares and sp 1000) ... while i do not expect IQAI to go this far, it does show how AI can be a winner in the medical/tech market
-- BB --

Sounds good to me
-- BB--

I'm not even in this share and I am excited for you!!!
-- BB --

if it were a dead horse ... then TB ... Trevor the B*stard ... would have surely sold out his 30% at 20 pence and made a lovely, easy £10 MILLION pounds? he didn't ... maybe Trevor the Brain knows what he is talking about ...
-- BB --

states £1 million in buys yet around the same in sells ... down 25% ...
hmmm
-- BB --

how many shades of IQAI beige did you use?
-- BB --

Hmmm ... something and nothing ... but something ...
· Cash reserves of ~£7.0 million as at 31 December 2020, no debt and a tax receivable of £0.7 million (31 Dec 2019: £9.2 million) which allows the Company ample headroom to continue to pursue its business development activities.
· Longboat is currently participating in a number of potential acquisition processes where we have unique knowledge and can take advantage of the continuing market dislocation.
· Several processes have been launched recently and we expect more assets to come to market as vendors seek to take advantage of the uptick in commodity prices.
-- BB --

"IQAI spots cat up tree" ... up 15% no doubt ...

IQAI and TeraRecon enter into a revised distribution agreement for IB Software. One of the more substantial changes is that IB personnel will engage earlier in the sales process to help explain the underlying technology and clinical application of its quantitative tools. --- what the bloomin' 'eck does this mean????????
-- BB --

hmmm
-- BB --

France and CBD will be of interest ...
-- BB --

this afternoon's presentation will guide us ...
-- BB --

Bravo holders ... I don't hold but excellent news for you all!
-- BB --

Cheryl Calverley, CEO of eve Sleep, commented:
"eve's rebuild strategy is essentially complete, six months ahead of plan. We move now to accelerate our business, with a mind to leveraging our strong brand, efficient marketing, high performing products and excellent customer service to allow us to diversify across markets, channels and categories.
-- BB --